NFKB1 and neoplasm: Li et al. [31] demonstrated that TGM-3 can be a candidate tumour suppressor that is able to induce EC cell proliferation and migration by down regulating the NF-κB signalling pathway, indicating that TGM-3 may serve as a useful biomarker and therapeutic target for esophageal cancer treatment.